G to C transition at position -173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation

Ya Yi Chang, Hildegard T. Greinix, Anne M. Dickinson, Daniel Wolff, Graham H. Jackson, Reinhard Andreesen, Ernst Holler, Gerhard C. Hildebrandt

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Pro-inflammatory and dendritic cell-activating properties of macrophage migration inhibitory factor (MIF) suggest a potentially important role for MIF in alloantigen-specific immune responses after allogeneic stem cell transplantation (allo-SCT). We tested whether MIF -173 G/C gene polymorphism of donor or patient had impacts on the outcomes after allo-SCT. Four hundred and fifty-four donor-patient pairs were genotyped and mortality, relapse, and development of complications were analyzed. Patient but not donor MIF -173*C allele was associated with improved overall survival (OS) (5 years: 60.8% versus 46.3%, p = 0.042) and disease free survival (DFS) (5 years: 55.4% versus 39.5%; p = 0.014) due to a reduction in relapse (day 2000: 22.8% versus 42.0% p = 0.006) but not due to decreased transplantation-related mortality (TRM) (p = 0.44). Multivariate analysis proved patient -173*C allele as an independent factor for reducing relapse after allo-SCT (p = 0.023). Subgroup analysis showed a clear MIF -173*C allele-related reduction in relapse for those patients who did not receive T cell depleted (TCD) SCT (p = 0.01) in contrast to patients receiving TCD SCT (p = 0.20). In summary, patient MIF -173*C allele may be linked to specific, yet unrevealed functions in tumor biology and graft versus leukemia and lymphoma effects and potentially presents a novel prognostic marker for patient-tailored counseling and therapy in allo-SCT.

Original languageEnglish
Pages (from-to)218-225
Number of pages8
Issue number3
StatePublished - Dec 2009

Bibliographical note

Funding Information:
The authors thank the statistician Dr. Ch. Ehret from the Department of Hematology and Oncology Clíncial Trials Office for his advice and Dr. F. Finger for collecting patient information. G.C.H. is a Max Eder Scholar of the Deutsche Krebshilfe e.V. as well as a Research Fellow of the European Hematology Association (EHA). This work was partially supported by European Community Grants TRANSEUROPE contract no QLRT-CT-2001-01936; TRANS-NET, contract no MRTN-CT-2004-512253 and STEMDIAGNOSTICS, contract no LSHB-CT-2007-037703.


  • Allogeneic
  • MIF
  • Polymorphism
  • Relapse
  • Stem cell transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Biochemistry
  • Molecular Biology
  • Hematology


Dive into the research topics of 'G to C transition at position -173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation'. Together they form a unique fingerprint.

Cite this